Deputy Speaker, in term of what we have, evidence available to us, it is the investment in the production of - what I've called - Active pharmaceutical ingredients. That is where the cost of medication needs to be looked.
In terms of looking at how to achieve more affordable medicine that hon Singh spoke about, you will probably need beyond the question of Active pharmaceutical ingredients, you need a legal framework that allows early licensing so that various companies can manufacture early. Once you have got that open and you have got good competition at that level, you may be able to get better prices.
Now, there has always been a big debate from the point of view of Treasury in terms of the involvement of the Department of Health in direct participation of manufacturing of drugs or of some products. And that has really been an issue of the department should not be part of a regulator, a user and player at the same time. So, there are those issues that we have to deal with in terms of our current legislation.
But in terms of needing to get medication t more affordable prices, there are many ways of being able to do that. We have assigned SAHPRA to be able to look into that matter and give us a kind of strategy that will open up South Africa to be a proper pharmaceutical manufacturing hub at the same time ensuring that we have got more affordable medicine. Thank you.